Intercept Stock Price Skyrockets On Continuing Stream Of Good Data For OCA Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Early stop due to efficacy of NIH Phase II trial in non-alcoholic steatohepatitis could mean quick pathway to approval for compound in this unmet medical need. A growing liver disease, Intercept believes NASH is an under-recognized opportunity, which could outstrip HCV and cirrhosis as a cause of liver transplantation.
You may also be interested in...
Enterome Extends Its Microbiome Platform
The French firm has partners for its diagnostics, wants to spin out a "stool banking" company, and might follow other microbiome start-ups into drug discovery to explore the connections between our bugs and our immune system.
A Pair Of Biotechs Bet On The IPO Market
Kythera and Intercept completed initial public offerings on the same day, both garnering prices at the high end of their anticipated offering ranges.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.